Logo image
Disease-modifying therapeutic directions for Lewy-Body dementias
Journal article   Open access   Peer reviewed

Disease-modifying therapeutic directions for Lewy-Body dementias

Qiang Zhang, Young-Cho Kim and Nandakumar S Narayanan
Frontiers in neuroscience, Vol.9, pp.293-293
2015
DOI: 10.3389/fnins.2015.00293
PMCID: PMC4542461
PMID: 26347604
url
https://doi.org/10.3389/fnins.2015.00293View
Published (Version of record) Open Access

Abstract

Dementia with Lewy bodies (DLB) is the second leading cause of dementia following Alzheimer's disease (AD) and accounts for up to 25% of all dementia. DLB is distinct from AD in that it involves extensive neuropsychiatric symptoms as well as motor symptoms, leads to enormous societal costs in terms of direct medical care and is associated with high financial and caregiver costs. Although, there are no disease-modifying therapies for DLB, we review several new therapeutic directions in treating DLB. We discuss progress in strategies to decrease the level of alpha-synuclein, to prevent the cell to cell transmission of misfolded alpha-synuclein, and the potential of brain stimulation in DLB.
Parkinson's disease Dementia with Lewy Bodies Psychiatry Alzheimer's disease Deep Brain Stimulation disease-modifying therapy

Details

Metrics

Logo image